As of December, 2012, these drugs have generally failed in trials, either causing a marked increase in deaths (Torcetrapib), or having no meaningful clinical improvement despite HDL increases (Dalcetrapib).
•
Dalcetrapib, development halted in May 2012 when Phase III trials failed to show clinically meaningful efficacy.
A compound related to torcetrapib, Dalcetrapib (investigative name JTT-705/R1658), was also being studied, but trials have since been ceased.